Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.
Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Infusion of apelin | Experimental | Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones. |
|
| Sodium nitroprusside infusion | Active Comparator | Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Angiotensin II | Drug | Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in angiotensin II mediated vasoconstriction | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in relevant neurohumoral hormones in response to apelin infusion | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Lack of informed consent
Age < 18 years,
Current involvement in other research studies,
Systolic blood pressure >190 mmHg or <100 mmHg
Malignant arrhythmias
Renal or hepatic failure
Haemodynamically significant aortic stenosis
Severe or significant co morbidity
Women of childbearing potential.
Any regular medication
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gareth D Barnes, MBChB | University of Edinburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc | Edinburgh | EH16 4SA | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D000783 | Aneurysm |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000804 | Angiotensin II |
| ID | Term |
|---|---|
| D000809 | Angiotensins |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Noradrenaline infusion | Drug | Infusion of up to 480 picomol/ml of noradrenaline will be infused. |
|
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |